Share
CytoSorb® is CE-mark approved in the E.U. In the U.S., CytoSorb® and DrugSorb-ATR® are investigational devices not yet FDA authorized/approved/cleared.
Overview

The Therapeutic Aspects of CytoSorb Therapy

Supporting healthcare professionals in maintaining physiological balance.

CytoSorb® Therapy provides a hemoadsorption option designed to support the reduction of selected inflammatory mediators, helping to maintain physiological stability in critically ill patients. The therapy is intended to remove or reduce excessive levels of inflammatory mediators, bilirubin and myoglobin that, at elevated levels, may be harmful to the body. Published clinical experience has reported associations with parameters such as hemodynamic stability, tissue perfusion, and organ function when CytoSorb Therapy is applied as part of a multimodal critical-care approach.

The CytoSorb® adsorber is an extracorporeal blood purification technology designed to reduce selected substances from blood or plasma that, at excessive levels, may be harmful to the body. It can be used in various clinical settings where hemoadsorption may support the management of substance-related imbalances as part of a multimodal treatment strategy.

  • CytoSorb® Therapy provides a hemoadsorption option designed to support the reduction of selected inflammatory mediators, helping to maintain physiological stability in critically ill patients. The therapy is intended to remove or reduce excessive levels of inflammatory mediators, bilirubin and myoglobin that, at elevated levels, may be harmful to the body. Published clinical experience has reported associations with parameters such as hemodynamic stability, tissue perfusion, and organ function when CytoSorb Therapy is applied as part of a multimodal critical-care approach.

  • The CytoSorb® adsorber is an extracorporeal blood purification technology designed to reduce selected substances from blood or plasma that, at excessive levels, may be harmful to the body. It can be used in various clinical settings where hemoadsorption may support the management of substance-related imbalances as part of a multimodal treatment strategy.

Here, you can find more information on CytoSorb® Therapy and its application across different medical specialties. This section includes details on patient selection, timing, and dosing, as well as access to current published clinical research.

Use of CytoSorb in therapeutic areas

  • Critical Care
  • Cardiovascular Care
  • Liver Care
  • Kidney Care
  • Critical Care

    Intended to remove cytokines and bilirubin to support management of systemic inflammatory responses.

  • Cardiovascular Care

    May be used in patients at risk of hyperinflammatory responses or intra-operatively during CPB to adsorb certain antithrombotic agents such as ticagrelor or rivaroxaban.

  • Liver Care

    Intended to remove selected cytokines, bilirubin, and other hydrophobic metabolites to support management of hyperbilirubinemia and systemic inflammation.

  • Kidney Care

    Intended to adsorb selected cytokines and myoglobin, either as a stand-alone modality or combined with renal-replacement therapies as part of a multimodal approach.

Documented safety

Over 300,000 hemoadsorption treatments over the last ten years.

Most peer-reviewed adsorber

Over 1,100 publications, abstracts, posters, manuscripts, and other resources.

Simple system integration

Starting patient treatment with CytoSorb technology is fast and easy, with less work for nurses, and greater peace of mind.

Proprietary bead technology

Each CytoSorb cartridge features ISO 10993-certified porous polymer beads, for biocompatibility and hemocompatibility.

Concentration-dependent and size-dependent removal

Effective removal of cytokines, bilirubin, myoglobin, rivaroxaban, and ticagrelor—and minimal removal of important substances such as albumin.

NON US HEALTHCARE PROFESSIONALS AREA

This section of the website contains medical and clinical information regarding products that are not cleared or approved by the U.S. Food and Drug Administration (FDA).

Under U.S. federal law, including the Federal Food, Drug, and Cosmetic Act (FD&C Act), dissemination of information about medical devices that are not FDA-cleared or approved for use in the United States may constitute unlawful promotion or misbranding if directed to U.S. healthcare professionals.
 
Accordingly:

This content is intended solely for Healthcare Professionals located outside the United States and Canada.

The products described are not approved or cleared in the United States or Canada for any indication.

Access by U.S. Healthcare Professionals is not permitted.
 

BY PROCEEDING, YOU CONFIRM THAT YOU ARE:
A licensed Healthcare Professional, and located outside the United States and Canada.

Physician experience, clinical practice patterns, risks, and patient outcomes may vary. The information presented reflects individual clinical experience and does not constitute medical advice.